PIK3CA and breast cancer: Finally, in a matrix in vitro screen of several miRNAs and drugs in BC, miR-126 augmented the potency of CDK4/6 or PIK3CA inhibitors in MCF7 (Luminal) and MDA-MB-453 (HER2+) cell lines (470).